KRYS250117C210000
- 0.50
- +0.10+25.00%
Krystal Biotech Newsroom
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $196
Promising Clinical Data and Platform Potential Drive Buy Rating for Krystal Biotech
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
Krystal Biotech Is Maintained at Buy by Chardan Capital
Krystal Biotech Early Lung Cancer Data 'Promising,' Says H.C. Wainwright
Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity
Express News | Krystal Biotech Announces Initial Results From Ongoing KYANITE-1 Study Of KB707; Observed 27% Objective Response Rate And 73% Disease Control Rate As Of Data Cut-Off On Dec. 6
Express News | Krystal: Majority of Treatment-Related Adverse Events Been Mild to Moderate in Severity & Transient, With No Grade 4 or 5 Adverse Events Observed
Express News | Krystal Biotech Inc - Reports 27% Orr and 73% Dcr in Nsclc Trial
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients With Advanced Non-Small Cell Lung Cancer
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.24 Million in Common Stock
Insider Sale: President of $KRYS (KRYS) Sells 911 Shares
Express News | Form 144 | Krystal Biotech(KRYS.US) Director Proposes to Sell 4.34 Million in Common Stocks
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
Krystal Biotech Announces Initial Update for KB408, KB407
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating